Ebola at 7,000: the collapse no one is watching

The Democratic Republic of Congo’s worst Ebola epidemic on record has passed 7,000 confirmed cases, Al Jazeera reported on Saturday, even as the government publicly insists case numbers are declining. The virus has spread to a seventh DRC province, extending its geographic footprint to cover a swath of territory roughly the size of France. The outbreak, which has been running for over a year, dwarfs the 2014–16 West Africa epidemic in case count and has evolved in a context of chronic underfunding, active conflict in the affected eastern provinces, and the progressive dismantling of the global health infrastructure that was built — at significant expense — in the aftermath of 2014. The WHO has maintained a Public Health Emergency of International Concern designation since earlier this year, but international media coverage and donor funding have been conspicuously thin.

The received wisdom

The mainstream public health framing emphasises the structural barriers: the DRC’s healthcare system was already overwhelmed before the current outbreak, conflict between the M23 rebel movement and government forces has disrupted vaccine delivery and health worker access in key provinces, community distrust of health authorities — partly a legacy of previous response failures — has slowed contact tracing, and the mutation of the virus strain has complicated vaccine efficacy calculations. International donors, the argument goes, have provided what resources they can in a challenging operating environment, and the focus should be on ceasefire negotiations and humanitarian corridors rather than on attributing blame. The WHO and Médecins Sans Frontières are doing their best in impossible conditions.

A different read

All of this is true, and none of it explains why 7,000 cases of one of the world’s most lethal pathogens barely registered on the front pages of Western newspapers this week, while a drone attack on a Saudi pipeline commanded immediate global attention. The disparity is not merely editorial. It reflects a deep structural asymmetry in how the international community allocates attention and resources: events that affect energy prices and geopolitical balances in regions strategically significant to Western interests receive immediate mobilisation; slow-motion catastrophes in the eastern DRC receive NGO press releases.

The argument that the international community “can’t do more” in an active conflict zone is empirically weaker than its proponents admit. The 2014 West Africa outbreak — in Guinea, Sierra Leone, and Liberia — occurred in countries with similarly weak health systems and, in Liberia’s case, fresh from a civil war. The international response that eventually contained it involved a genuine emergency mobilisation: US military deployment to build Ebola treatment units, a coordinated WHO-led incident management structure, and aggressive donor pledging that created functional capacity on the ground. None of this happened quickly or smoothly, but it happened. The current DRC outbreak has not seen anything comparable. The US Centers for Disease Control, significantly reduced in capacity and international deployment capability following the cuts of recent years, is operating at a fraction of its 2014 footprint.

There is a pharmaceutical dimension that deserves attention. The rVSV-ZEBOV vaccine (Ervebo) was approved following the 2018 DRC outbreak and represents a genuine advance. But vaccine efficacy against the Bundibugyo strain variant now circulating in the seventh province is under active scientific review. If the virus has mutated sufficiently to reduce Ervebo’s protection, the international community is operating on the assumption of a tool that may no longer fully work — and the time to manufacture and trial an updated formulation is measured in months, not days.

The political economy of global health is also relevant here. The major donors to WHO and to outbreak response mechanisms — the United States, the European Union, the UK — have all cut global health spending in real terms over the past four years. The WHO’s emergency preparedness fund is capitalised at a fraction of what independent reviews have said is necessary. When the Ebola response is under-resourced, it is not because the money does not exist globally — it is because political leaders in wealthy democracies have concluded that spending on infectious disease prevention in central Africa does not generate electoral returns. This is a rational calculation from a narrow domestic politics perspective. From the perspective of anyone who remembers 2014, or indeed 2020, it is also extraordinarily short-sighted.

The DRC government’s insistence that cases are declining, contradicted by the reported spread to a seventh province, should be treated with appropriate scepticism. Governments facing legitimacy crises do not tend to communicate accurately about catastrophes unfolding on their watch. The gap between official reassurance and epidemiological reality is itself a warning sign: it suggests the response capacity is insufficient to generate the data needed to know what is actually happening, let alone to contain it.

What to watch

Three developments will determine whether this remains a contained, if catastrophic, regional crisis or becomes something with genuine global implications. First, whether the Bundibugyo strain’s apparent vaccine-escape properties are confirmed by WHO’s technical advisory group — a finding that would require an immediate emergency research mobilisation. Second, whether any case is confirmed in a major urban hub outside the eastern provinces: Kinshasa, Goma, or a neighbouring country’s border city would change the calculus entirely. Third, whether any Western government — perhaps Canada or the UK, neither of which has the domestic political tensions around global health that currently constrain Washington — steps up to fill the CDC capacity gap with a serious funded commitment. The epidemiological window for containment narrows with each new provincial spread.

— J